Pliant Therapeutics to Join Investor Events - May 1, 2024

SOUTH SAN FRANCISCO, Calif., May 01, 2024-- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company specializing in the development of innovative treatments for fibrotic diseases, has announced its participation in several investor events scheduled for May.

At the RBC Capital Markets Global Healthcare Conference, Bernard Coulie, M.D., Ph.D., President and Chief Executive Officer of Pliant, along with Éric Lefebvre, M.D., Chief Medical Officer, will engage in a fireside chat on Tuesday, May 14, 2024, at 1:35 p.m. Eastern Time.

The company will also be represented on the Stifel West Coast Bus Tour on Thursday, May 23, 2024. Members of Pliant's senior management team will meet with investors during this exclusive, invitation-only event hosted by Stifel.

Additionally, at the Piper Sandler Virtual Lung Investor Day, Keith Cummings, M.D., Chief Financial Officer, and Greg Cosgrove, M.D., Vice President of Clinical Development, will participate in a fireside chat, also on Thursday, May 23, 2024. This event is another invitation-only gathering facilitated by Piper Sandler.

For those interested in the RBC fireside chat, a live webcast will be available on Pliant’s Investor Relations’ Events & Presentation page. The webcast replay will be accessible on Pliant's website for 30 days after the event.

Pliant Therapeutics is at the forefront of developing treatments for fibrotic diseases. Its flagship product, bexotegrast (PLN-74809), is an oral, small-molecule, dual-selective inhibitor of αvß6 and αvß1 integrins. This drug is being developed to treat idiopathic pulmonary fibrosis (IPF) and primary sclerosing cholangitis (PSC). Bexotegrast has been granted Fast Track Designation and Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) for both IPF and PSC. Additionally, it has received Orphan Drug Designation from the European Medicines Agency for the same conditions. Pliant has initiated a Phase 2b/3 trial, known as the BEACON-IPF study, for bexotegrast in IPF.

Another promising candidate from Pliant is PLN-1474, a selective inhibitor of αvß1 integrin, aimed at treating metabolic dysfunction-associated steatohepatitis (MASH). Pliant has also started a Phase 1 clinical trial for its third program, PLN-101095. This drug is a dual-selective inhibitor of αvß8 and αvß1 integrins, being developed for solid tumor treatment.

Beyond these clinical-stage programs, Pliant is also working on a preclinical program targeting muscular dystrophies, further emphasizing the company’s commitment to addressing severe and challenging health conditions.

Pliant Therapeutics continues to make significant strides in the biopharmaceutical industry, leveraging its expertise in integrin biology to develop novel therapeutics aimed at improving the lives of patients suffering from fibrotic diseases and other serious conditions. The upcoming investor events will provide a platform for the company to share its progress and future plans with the investment community.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!